Although inhibitor of apoptosis (IAP) proteins were initially described to function as endogenous caspase inhibitors,^[@bib1]^ X-linked IAP (XIAP) but not cellular IAP1 (cIAP1) and cIAP2 possesses the critical residues for direct inactivation of caspases.^[@bib2]^ In addition, IAP proteins exert additional functions besides inhibiting apoptosis, for example, regulation of cell motility, migration and invasion, although their role in this context has been controversially discussed. On one side, XIAP was reported to exert a pro-migratory function in endothelial cells,^[@bib3]^ to be required for cell motility by regulating actin polymerization^[@bib4]^ and to cooperate with survivin to foster cell motility and invasion.^[@bib5]^ Also, cIAP1 was shown to regulate cell migration in a CARD-dependent manner, as mutation of its CARD domain increased cell migration.^[@bib6]^ On the other side, downregulation of XIAP or cIAPs either by siRNA-mediated knockdown or utilization of second mitochondrial activator of caspases (Smac) mimetic were recorded to promote cell migration via phosphorylation of C-RAF and activation of the MAPK signaling cascade.^[@bib7]^ In addition, depletion of XIAP or cIAP1 was shown to trigger Rac1 accumulation, thereby enhancing cell elongation and migration.^[@bib8]^

Furthermore, IAP proteins are key regulators of canonical and non-canonical nuclear factor-*κ*B (NF-*κ*B) pathways.^[@bib1]^ In resting cells, canonical NF-*κ*B signaling is blocked by I*κ*B*α*, which sequesters NF-*κ*B subunits in the cytosol.^[@bib9]^ On tumor necrosis factor (TNF) receptor 1 (TNFR1) activation, I*κ*B*α* gets phosphorylated and degraded, leading to p65/p50 nuclear translocation and transcriptional activation of NF-*κ*B target genes. E3 ligase activity of cIAP proteins promotes activation of canonical NF-*κ*B signaling by adding K63-linked ubiquitin chains on RIP1 kinase.^[@bib10],\ [@bib11]^ In the non-canonical NF-*κ*B pathway, NF-*κ*B-inducing kinase (NIK) is constitutively degraded via a cIAP/TRAF complex.^[@bib12],\ [@bib13]^ Downregulation of cIAP proteins leads to NIK accumulation, processing of p100 to p52, nuclear translocation of p52 and NF-*κ*B activation.^[@bib14],\ [@bib15]^ NF-*κ*B can control migration and invasion via transcriptional activation of pro-migratory and pro-invasive genes like CXC chemokines, urokinase-type plasminogen activator (uPA) and matrix metalloproteinases (MMPs).^[@bib16]^

Glioblastoma (GBM) is the most frequent malignant brain tumor with a very poor prognosis and its aggressiveness involves a highly migratory and invasive phenotype.^[@bib17],\ [@bib18]^ Constitutively activated NF-*κ*B has been linked to its invasive behavior and degree of malignancy.^[@bib19],\ [@bib20]^

Overexpression of IAP proteins correlates with poor prognosis and treatment resistance of cancers.^[@bib4],\ [@bib21],\ [@bib22]^ Chromosomal amplification of 11q22. containing the loci of cIAP1/2 often occurs in GBM^[@bib23]^ and IAP proteins are overexpressed in GBM cell lines.^[@bib24]^ During apoptosis, IAP proteins are antagonized by Smac that is released from the mitochondria.^[@bib25],\ [@bib26]^ Similarly, small-molecule Smac mimetics bind and neutralize IAP proteins.^[@bib1]^ In this study, we investigated the role of the Smac mimetic BV6 in the regulation of migration and invasion using GBM as a model.

Results
=======

BV6 at non-toxic concentration stimulates cell elongation of GBM cells
----------------------------------------------------------------------

To investigate whether non-toxic concentrations of the Smac mimetic BV6 regulates additional pathways besides apoptosis in GBM cells, we initially determined its non-lethal concentrations. Concentrations of BV6 up to a 2.5 *μ*M had no effect on cell viability or caspase-3 activation ([Figures 1a and b](#fig1){ref-type="fig"}). To control the biological activity of BV6 at these conditions we assessed IAP protein levels, because BV6 triggers autoubiquitination of IAP proteins.^[@bib14]^ BV6 caused profound depletion of cIAP1 protein in all three cell lines consistent with a previous report that cIAP1 is especially susceptible to Smac mimetic-stimulated degradation.^[@bib14],\ [@bib15],\ [@bib27]^ In addition, BV6-triggered degradation of XIAP and cIAP2 in T98G and LN229 cells, whereas U87MG cells showed no changes in XIAP levels and little expression of cIAP2 protein ([Figure 1b](#fig1){ref-type="fig"}). Therefore, we used 2.5 *μ*M BV6 for all subsequent experiments as a non-toxic concentration that causes depletion of cIAP proteins.

To examine the effect of BV6 on non-apoptotic functions, we monitored the morphology of T98G cells by time-lapse microscopy. Interestingly, we observed that treatment with BV6-stimulated cell elongation with long cytoplasmic extensions compared with control cells with round shape and short cytoplasmic extensions ([Figures 1c and d](#fig1){ref-type="fig"}). To analyze actin polymerization as a typical feature of cell motility, we stained cells for filamentous actin (F-actin). Confocal microscopy showed that BV6-treated T98G cells exhibited long F-actin-rich protrusions suggesting that BV6 stimulates changes in the cytoskeleton that are associated with cell motility ([Figure 1e](#fig1){ref-type="fig"}). Thus, BV6 at a sublethal concentration stimulates cell elongation of GBM cells.

BV6 at non-toxic concentration triggers migration and invasion of GBM cells and increases infiltrative growth of GBM *in vivo*
------------------------------------------------------------------------------------------------------------------------------

Based on our findings that BV6 stimulates morphological changes associated with increased cell motility, we next investigated whether BV6 has an effect on migration and invasion of GBM cells. Transwell migration assays showed that BV6 significantly increased migration of T98G, U87MG and LN229 cells ([Figures 2a and b](#fig2){ref-type="fig"}). In addition, BV6 significantly enhanced invasion of GBM cells ([Figure 2c](#fig2){ref-type="fig"}). To control that these BV6-stimulated changes in migration and invasion were not simply because of alterations in proliferation and/or cell cycle, we monitored these parameters in parallel. BV6 did not significantly change proliferation ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}) or cell cycle distribution ([Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}) at non-toxic conditions. Taken together, these data demonstrate that BV6 triggers migration and invasion of GBM cells.

Next, we asked whether BV6 also stimulates invasiveness of GBM cells *in vivo*. To address this question we used the chicken chorioallantoic membrane (CAM) model, an established preclinical tumor model.^[@bib28],\ [@bib29]^ T98G cells were treated for 24 h with BV6 and were then seeded on the CAM of chicken embryos to allow tumor growth *in vivo,* which was assessed after 4 days. Importantly, pre-treatment of GBM cells with BV6 substantially increased the percentage of tumors with infiltrative growth *in vivo* compared with tumors derived from untreated GBM cells ([Figure 2d](#fig2){ref-type="fig"}). These data indicate that BV6 increases the infiltrative growth of GBM cells *in vivo*.

BV6 at non-toxic concentration activates the NF-*κ* B pathway
-------------------------------------------------------------

Next, we aimed at identifying the underlying molecular mechanisms responsible for the BV6-stimulated cell elongation, migration and invasion. To this end, we examined the effect of BV6 on NF-*κ*B signaling, because BV6-mediated downregulation of IAP proteins has been reported to lead to NF-*κ*B activation.^[@bib14]^ To monitor activation of the canonical NF-*κ*B pathway, we analyzed I*κ*B*α* phosphorylation. I*κ*B*α* was slightly phosphorylated after 2 h of BV6 stimulation accompanied by a slight decrease in I*κ*B*α* protein levels ([Figure 3a](#fig3){ref-type="fig"}). As positive control for canonical NF-*κ*B signaling, we used TNF*α*, which potently stimulated phosphorylation and degradation of I*κ*B*α* protein already after 5 min ([Figure 3a](#fig3){ref-type="fig"}). For monitoring non-canonical NF-*κ*B activation, we assessed accumulation of NIK protein and proteolytic processing of p100 to p52. BV6 rapidly caused accumulation of NIK and processing of p100 to p52 ([Figure 3b](#fig3){ref-type="fig"}). NIK accumulation and p100 processing to p52 was similarly detected in all three GBM cell lines ([Figure 3c](#fig3){ref-type="fig"}). To analyze that NF-*κ*B subunits translocate into the nucleus, we prepared cytosolic and nuclear extracts. BV6 stimulated nuclear translocation of p52 and p50 and slightly that of p65, whereas TNF*α* primarily triggered p65 translocation ([Figure 3d](#fig3){ref-type="fig"}). DNA-binding assays showed that BV6 stimulated NF-*κ*B DNA binding within the first hours of stimulation and over a prolonged time up to at least 24 h ([Figure 3e](#fig3){ref-type="fig"}). Interestingly, electrophoretic mobility shift assay (EMSA) supershift assay revealed that NF-*κ*B DNA-binding complexes on stimulation with BV6 were mainly composed of p50, p52 and RelB subunits, because the addition of p50, p52 and/or RelB antibodies to nuclear extracts resulted in a supershift (for p50 antibody) or immunodepletion (for p52 and/or RelB antibodies) of DNA-binding complexes ([Figure 3f](#fig3){ref-type="fig"}). By comparison, p65 contributed to a minor extent to BV6-triggered NF-*κ*B complex formation, indicating that BV6 mainly triggers non-canonical NF-*κ*B signaling. As prototypic stimulus of the canonical NF-*κ*B pathway, TNF*α*-triggered increased DNA-binding of the p65 subunit and also of p50 ([Figure 3f](#fig3){ref-type="fig"}). To determine whether NF-*κ*B DNA-binding leads to transcriptional activation of NF-*κ*B target genes we performed luciferase assay. BV6 significantly increased NF-*κ*B transcriptional activity ([Figure 3g](#fig3){ref-type="fig"}). These experiments show that BV6 activates NF-*κ*B signaling and in particular the non-canonical pathway in GBM cells resulting in enhanced NF-*κ*B transcriptional activity.

NF-*κ*B is required for BV6-induced cell elongation, migration and invasio
--------------------------------------------------------------------------

We next asked whether NF-*κ*B activation is required for BV6-induced changes in cell shape and motility of GBM cells. To address this question, we overexpressed I*κ*B*α* superrepressor (I*κ*B*α*-SR) in T98G cells to inhibit NF-*κ*B ([Figure 4a](#fig4){ref-type="fig"}). Control experiments showed that I*κ*B*α* overexpression potently suppressed BV6- and TNF*α*-stimulated NF-*κ*B activation ([Figure 4b](#fig4){ref-type="fig"}) without altering cell viability on treatment with BV6 ([Supplementary Figure S1C](#sup1){ref-type="supplementary-material"}). Interestingly, inhibition of NF-*κ*B by I*κ*B*α*-SR resulted in increased NIK levels accompanied by profound downregulation of cIAP2 expression ([Figure 4c](#fig4){ref-type="fig"}). As cIAP2 is a prototypic NF-*κ*B target gene and functions in complex with TRAF2/3 as E3 ligase for NIK,^[@bib12],\ [@bib13]^ reduced cIAP2 expression on NF-*κ*B inhibition may account for stabilization of NIK protein. In addition, inhibition of NF-*κ*B by I*κ*B*α*-SR resulted in reduced expression of additional NF-*κ*B target genes, including p100, RelB and cIAP1 ([Figure 4c](#fig4){ref-type="fig"}).^[@bib30],\ [@bib31]^ As a side note, the short incubation time with BV6 to assess NIK accumulation (3 h) may account for the fact that treatment with BV6 did not yet result in depletion of cIAP2 protein in this experiment ([Figure 4c](#fig4){ref-type="fig"}) compared with cIAP2 degradation in parental T98G cells on prolonged incubation with BV6 for 24 h ([Figure 1b](#fig1){ref-type="fig"}). Importantly, NF-*κ*B inhibition prevented the BV6-stimulated cell elongation compared with control cells ([Figures 4d and e](#fig4){ref-type="fig"}). Also, the BV6-triggered increase in migration and invasion was blocked in I*κ*B*α*-SR-overexpressing cells compared with control cells ([Figures 4f and g](#fig4){ref-type="fig"}). Together, this set of experiments demonstrates that NF-*κ*B is required for BV6-stimulated cell elongation, migration and invasion.

TNF*α*/TNFR1 autocrine/paracrine signaling is required for BV6-induced cell elongation, migration and invasion
--------------------------------------------------------------------------------------------------------------

As TNF*α* is one of the key NF-*κ*B target genes and has been described to regulate migration and invasion,^[@bib16],\ [@bib32]^ we analyzed whether TNF*α* is upregulated on BV6 treatment. Quantitative RT-PCR analysis showed that within 3 h BV6 rapidly stimulated an increase in TNF*α* mRNA levels ([Figure 5a](#fig5){ref-type="fig"}). Besides TNF*α*, BV6 increased mRNA levels of additional NF-*κ*B target genes controlling cell migration, including the chemokines interleukin 8 (IL-8), monocyte chemoattractant protein 1 (MCP-1) and CXC chemokine receptor type 4 (CXCR4), or regulating migration such as the protease MMP9, whereas little or no changes in uPA and MMP2 mRNA levels were found ([Figure 5b](#fig5){ref-type="fig"}).

To test whether TNF*α*/TNFR1 signaling is required for the BV6-induced cell elongation, migration and invasion, we used the soluble TNF*α* antibody Enbrel as a pharmacological approach to abolish a putative TNF*α* autocrine/paracrine signaling loop. Control experiments showed that Enbrel neither alone nor in combination with BV6 was cytotoxic to T98G cells ([Supplementary Figure S2A](#sup1){ref-type="supplementary-material"}), whereas it potently blocked DNA fragmentation after co-treatment with BV6 and TNF*α* that was used as a positive control for Enbrel ([Supplementary Figure S2B](#sup1){ref-type="supplementary-material"}). Interestingly, the addition of Enbrel inhibited the BV6-stimulated increase in cell elongation, migration and invasion, whereas Enbrel alone had no effect on these parameters ([Figures 5c--e](#fig5){ref-type="fig"}). In a second genetic approach to block TNF*α*/TNFR1 signaling, we knocked down TNFR1 by RNA interference ([Figure 6a](#fig6){ref-type="fig"}). Control experiments showed that TNFR1 knockdown did not affect sensitivity towards BV6, whereas it significantly reduced DNA fragmentation after co-treatment with BV6 and TNF*α* that was used as a positive control for TNFR1 knockdown ([Supplementary Figures S2C, S2D](#sup1){ref-type="supplementary-material"}). Importantly, TNFR1 knockdown prevented the BV6-induced cell elongation, migration and invasion, whereas BV6 significantly increased cell elongation, migration and invasion in non-silencing control cells ([Figures 6b--d](#fig6){ref-type="fig"}). To investigate whether increased mRNA levels of IL-8, MCP-1 and MMP9 are also a consequence of TNF*α* autocrine/paracrine signaling, we determined mRNA levels of these cytokine genes in the presence and absence of Enbrel. The addition of Enbrel reduces the BV6-triggered upregulation of IL-8, MCP-1 and MMP9 mRNA levels ([Supplementary Figure S2E](#sup1){ref-type="supplementary-material"}) indicating that TNF*α* autocrine/paracrine signaling is involved in BV6-induced increase in IL-8, MCP-1 and MMP9 expression. Together, this set of experiments demonstrates that BV6 increases the expression of NF-*κ*B target genes including TNF*α*, which in turn engages a TNF*α*/TNFR1 autocrine/paracrine signaling loop that is required for the BV6-induced cell elongation, migration, invasion and induction of NF-*κ*B target genes.

NIK is required for BV6-induced cell elongation, migration and invasion
-----------------------------------------------------------------------

To further investigate the role of the non-canonical NF-*κ*B pathway, we created T98G cells with knockdown of NIK (shNIK; [Supplementary Figure S3A](#sup1){ref-type="supplementary-material"}). Control experiments showed that NIK knockdown reduced BV6-stimulated NIK accumulation, p100 processing to p52 and NF-*κ*B DNA-binding compared with non-silencing control cells ([Figures 7a and b](#fig7){ref-type="fig"}). By comparison, NIK silencing did not interfere with NF-*κ*B binding on TNF*α* stimulation ([Figure 7b](#fig7){ref-type="fig"}), consistent with activation of the canonical NF-*κ*B pathway by TNF*α* ([Figures 3a and f](#fig3){ref-type="fig"}). Control experiments also showed that NIK knockdown did not alter the sensitivity toward BV6 compared with control cells ([Supplementary Figure S3B](#sup1){ref-type="supplementary-material"}). Importantly, NIK silencing prevented BV6-stimulated increase in cell elongation, migration and invasion compared with control cells ([Figures 7c--e](#fig7){ref-type="fig"}).

As our results show that TNF*α* is upregulated on BV6 treatment ([Figure 6a](#fig6){ref-type="fig"}) and required for BV6-stimulated cell elongation, migration and invasion ([Figures 6b--d](#fig6){ref-type="fig"}), we next analyzed whether TNF*α* levels increase in a NIK-dependent manner. Interestingly, BV6-stimulated upregulation of TNF*α* was strongly reduced in NIK knockdown cells compared with non-silencing control cells ([Figure 7f](#fig7){ref-type="fig"}). In addition, the BV6-mediated upregulation of IL-8, MCP-1 and MMP9 was profoundly suppressed in NIK knockdown cells ([Figure 7g](#fig7){ref-type="fig"}). These experiments indicate that NIK is required for BV6-induced cell elongation, migration, invasion and induction of NF-*κ*B target genes.

BV6 triggers cell elongation, migration and invasion in primary GBM cells
-------------------------------------------------------------------------

To test the potential clinical relevance of our findings, we extended our experiments to primary GBM cells derived from patients\' specimens. BV6 at low micromolar concentrations caused profound depletion of cIAP1 without altering cell viability or triggering caspase-3 cleavage, whereas BV6 had no or minor effects on expression levels of cIAP2 and XIAP ([Figures 8a and b](#fig8){ref-type="fig"}). Also, BV6 induced accumulation of NIK protein and p100 processing to p52, indicating that it stimulates non-canonical NF-*κ*B signaling in primary GBM cells ([Figure 8c](#fig8){ref-type="fig"}). Importantly, BV6 significantly increased cell elongation, migration and invasion of both GBM1 and GBM2 cells ([Figures 8d--f](#fig8){ref-type="fig"}). These findings demonstrate that BV6 at non-toxic concentrations activates the non-canonical NF-*κ*B pathway and triggers cell elongation, migration and invasion in primary GBM cells.

Discussion
==========

We previously reported that small-molecule IAP antagonists such as Smac mimetic act in concert with cytotoxic strategies including chemotherapeutics, TRAIL or irradiations to induce apoptosis in GBM cells.^[@bib33],\ [@bib34],\ [@bib35],\ [@bib36]^ Here, we report that the Smac mimetic BV6 as single agent at non-toxic concentrations exerts non-apoptotic functions in GBM cells: BV6 promotes cell elongation, migration and invasion of GBM cells by activating non-canonical NF-*κ*B signaling and a TNF*α*/TNFR1 autocrine/paracrine loop. This conclusion is supported by several independent pieces of evidence. First, treatment of GBM cells with BV6 results in predominant activation of the non-canonical NF-*κ*B pathway as demonstrated by accumulation of NIK protein, proteolytic processing of p100 to p52, translocation of p52 from the cytosol into the nucleus, binding of the NF-*κ*B subunits p52, p50 and RelB to the DNA, transcriptional activation of NF-*κ*B and increased mRNA expression of NF-*κ*B target genes including TNF*α*. By comparison, non-toxic concentrations of BV6 only slightly stimulate the canonical NF-*κ*B pathway in GBM cells. Second, overexpression of I*κ*B*α*-SR blocks activation of the non-canonical NF-*κ*B pathway and suppresses BV6-stimulated cell elongation, migration and invasion. Decreased expression levels of key components of the non-canonical NF-*κ*B pathway such as p100 and RelB, which are NF-*κ*B target genes,^[@bib30],\ [@bib31]^ may contribute to inhibition of non-canonical NF-*κ*B signaling in I*κ*B*α*-SR-overexpressing cells. Third, specific inhibition of the non-canonical NF-*κ*B pathway by RNAi-mediated knockdown of NIK inhibits the BV6-induced cell elongation, migration and invasion as well as upregulation of NF-κB target genes such as TNF*α*. Fourth, inhibition of the TNF*α*/TNFR1 autocrine/paracrine loop either by a pharmacological approach using the TNF*α*-blocking antibody Enbrel or by a genetic strategy via RNAi-mediated silencing of TNFR1 suppresses cell elongation, migration and invasion on exposure to BV6. Together, these data underscore the critical role of non-canonical NF-*κ*B signaling for BV6-stimulated cell elongation, migration and invasion.

The novelty of our study resides in the identification of the non-canonical NF-*κ*B pathway as a critical mediator of BV6-triggered cell elongation, migration and invasion of GBM cells. By monitoring activation of both the non-canonical and the canonical NF-*κ*B pathway at different levels of the signaling cascade, we demonstrate that non-toxic concentrations of BV6 predominately stimulate non-canonical NF-*κ*B signaling. This identification of non-canonical NF-*κ*B signaling as a key mediator of the non-apoptotic functions of BV6 in the control of migration and invasion is particularly interesting in comparison with previous studies reporting that non-canonical NF-*κ*B signaling is required for Smac mimetic-triggered cytotoxicity. This indicates that the non-canonical NF-*κ*B pathway is involved in the regulation of both non-apoptotic and apoptotic processes on treatment with Smac mimetic in a context-dependent manner. Of note, in this study we used non-toxic concentrations of BV6 that cause depletion of cIAP proteins and activation of the non-canonical NF-*κ*B pathway but do not affect cell viability or proliferation. Thus, Smac mimetic may differentially engage non-apoptotic and apoptotic pathways in a concentration-dependent manner. The slight activation of the canonical NF-*κ*B pathway in our model may occur via a crosstalk with the non-canonical NF-*κ*B pathway, because NIK has been described to also interact and phosphorylate IKK*β*, although IKK*α* is known as a preferential substrate for NIK.^[@bib37],\ [@bib38]^ Although the impact of the canonical NF-*κ*B pathway on migration and invasion has been extensively studied,^[@bib16]^ there are only a few reports on the role of non-canonical NF-*κ*B signaling in this context. In a murine system, IKK*α*^−/−^ or p52^−/−^ macrophages or mouse embryo fibroblasts were demonstrated to fail to migrate toward the chemoattractant HMGB1, as they were unable to maintain the production of CXCL12/SDF1.^[@bib39],\ [@bib40]^ Further, NIK was reported to be necessary for osteopontin-stimulated secretion of uPA, uPA-dependent activation of pro-MMP-9 as well as cell migration and invasion.^[@bib41]^

Another important finding of our study consists in the identification of a TNF*α*/TNFR1 autocrine/paracrine, non-apoptotic loop as critical mediator of BV6-stimulated migration and invasion, because all these effects are suppressed by the TNF*α*-blocking antibody Enbrel and in TNFR1 knockdown cells. Of note, TNF*α*/TNFR1 autocrine/paracrine signaling has been implicated to mediate apoptosis of Smac mimetic at lethal concentrations.^[@bib14],\ [@bib15]^ Thus, Smac mimetic may differentially engage non-apoptotic and apoptotic TNF*α*/TNFR1-mediated events in a context-dependent manner. TNF*α*/TNFR1-stimulated signaling may contribute to non-canonical NF-*κ*B activation during BV6-stimulated migration and invasion. In RIP1-deficient cells, TNFR1 crosslinking was shown to engage the non-canonical NF-*κ*B pathway via TRAF2 downregulation.^[@bib42],\ [@bib43]^ However, we found no evidence that TRAF2 expression decreases on BV6 stimulation (data not shown). Thus, further studies are required to explore whether TNF*α*/TNFR1 signaling is linked to non-canonical NF-*κ*B pathway in our model.

The role of IAP proteins in cell migration has been controversially discussed, as some studies reported that IAP proteins promote motility and migration,^[@bib3],\ [@bib5],\ [@bib6]^ whereas others -- similar to our findings -- demonstrated that migration is enhanced on depletion of IAP proteins.^[@bib7],\ [@bib8]^ How can these controversies be reconciled? It is interesting to note that these studies differ with respect to whether or not NF-*κ*B is activated and which NF-*κ*B pathway is predominantly engaged on depletion of IAP proteins. Although we found that BV6 primarily stimulates the non-canonical NF-*κ*B pathway, Mehrotra *et al.*^[@bib5]^ reported that XIAP and survivin act together to activate canonical NF-*κ*B signaling, whereas in another study Smac mimetic was shown to exert no effect on NF-*κ*B transcriptional activity.^[@bib6]^ The differences may also be explained by the balance in proliferation and cell death controlled by IAP proteins. As IAP proteins are key repressors of apoptosis, a decrease in their expression levels might promote cell death. This underscores the relevance of taking into consideration whether or not depletion of IAP proteins affects the rate of proliferation and/or cell death, as such effects may also have an impact on migration and invasion. Although we showed that non-toxic concentrations of BV6 do not alter proliferation, cell cycle progression or cell death, loss of cIAP1/2 was previously reported to reduce the proliferation rate.^[@bib6]^ Furthermore, the approach to antagonize IAP proteins in cancer cells, that is, via genetic manipulation of by pharmacological means, may affect the functional outcome. Also, the cellular context including differences in cell types (e.g., cancer *versus* non-malignant cells, mammalian *versus* murine models) may have an influence on the phenotype that is observed on depletion of IAP proteins. Moreover, the relative expression levels of distinct IAP proteins within the cells and the spectrum of IAP proteins that are neutralized by various Smac mimetics could encounter for differences in cellular responses.

Pharmacological antagonists of IAP proteins such as Smac mimetics are currently under evaluation in early clinical trials, thus highlighting the significance of studies to elucidate the impact of Smac mimetic on non-apoptotic as well as apoptotic functions. The potential clinical relevance of our findings is underlined by parallel experiments in primary GBM cells derived from patient-derived tumor specimens, which similarly demonstrate that BV6 at a non-lethal concentration activates non-canonical NF-*κ*B signaling and promotes cell elongation, migration and invasion. In addition, the BV6-stimulated increase in the invasiveness of GBM cells is reproduced in an *in vivo* model.

In summary, we identify non-canonical NF-*κ*B signaling as an important mediator of BV6-stimulated migration and invasion of GBM cells. These findings have important implications for the application of Smac mimetics as cancer therapeutics.

Materials and Methods
=====================

Cell culture and chemicals
--------------------------

Human GBM cell lines T98G, U87MG and LN229 were obtained from ATCC (Manassas, VA, USA) and grown in DMEM medium (Invitrogen, Karlsruhe, Germany) supplemented with 1% penicillin/streptomycin, 1% sodium pyruvate (both from Invitrogen) and 10% fetal calf serum (Invitrogen). The bivalent Smac mimetic BV6 (ref. 14) was kindly provided by Genentech (South San Francisco, CA, USA), recombinant human TNF*α* was purchased from Biochrom (Berlin, Germany), MG132 from Enzo Life Sciences (Lörrach, Germany). Enbrel was kindly provided by Pfizer (Berlin, Germany). All chemicals were obtained from Sigma (Deisenhofen, Germany) unless indicated otherwise.

Transduction
------------

Overexpression of the dominant-negative I*κ*B*α*-SR was performed by retroviral transduction using I*κ*B*α* (S32; 36A) and the pCFG5-IEGZ retroviral vector system as previously described.^[@bib44]^ Knockdown of NIK and TNFR1 was performed by lentiviral shRNA vectors as previously described.^[@bib45]^ Shortly, HEK293T cells were transfected with 7.5 *μ*g pGIPZ-shRNAmir vector, using calcium phosphate transfection. All pGIPZ-shRNAmir-vectors were purchased from Thermo Fisher Scientific (Dreieich, Germany) (non-silencing control (NS): RHS4346, shNIK shRNA: RHS4430-99889385, shTNFR1 shRNA: RHS4430-101168495). Virus-containing supernatant was collected, filtered and used for spin transduction at 30 °C in the presence of 8 *μ*g/ml polybrene. Transduced cells were selected with 1 *μ*g/ml puromycin (Sigma).

Determination of cell viability
-------------------------------

Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay according to the manufacturer\'s instructions (Roche Diagnostics, Mannheim, Germany).

Determination of cell elongation
--------------------------------

Cells were seeded in 12-well plates 1 day before stimulation. Directly after stimulation with BV6, live cell imaging was performed at 37 °C under 5% CO~2~ for 24 h using Leica DMI6000B microscope (Leica Microsystems, Wetzlar, Germany). Images were taken each 15 min and processed using Leica application suite. Three independent experiments were recorded. Three pictures of each condition of the 24 h time point were selected and cell length and width of 20 cells per picture were measured using ImageJ (National Institutes of Health (NIH), Bethesda, MD, USA). Cell elongation index was calculated by dividing the length by the width.

Determination of migration and invasion
---------------------------------------

In all, 1 × 10^5^ cells were seeded onto 8 *μ*m transwell migration chambers (Corning Inc., Wiesbaden, Germany), stimulated by adding 2.5 *μ*M BV6 both to the lower and the upper chambers to avoid any gradient effect and left to migrate for 24 h. Cells on the upper part of the membrane were scraped using a cotton swab. Migrated cells were fixed in 4% paraformaldehyde and stained with 0.4% crystal violet. For quantification, crystal violet staining was re-solubilized in a solution containing 1% SDS and absorbance was measured at 550 nm using a microplate reader (TECAN Infinite M200, Crailsheim, Germany).

For determination of invasion, cells were mixed with 1.7 mg/ml fluorescein (FITC)-conjugated collagen type I (Invitrogen) solution and seeded in a 48-well plate at the density of 1 × 10^6^ cells/ml. After polymerization of collagen, phenolred-free DMEM medium was added with 2.5 *μ*M BV6 or dimethylsulfoxyde (DMSO) for 24 h. As invasive cells degrade the extracellular matrix thereby releasing FITC-conjugated collagen into the supernatant, invasion was assessed by measuring absorbance of the supernatant at 520 nm using a microplate reader (TECAN Infinite M200). Invasion of cells expressing I*κ*B*α*-SR and NIK or TNFR1 knockdown cells was analyzed using transwell migration chambers pre-coated with collagen (1.4 mg/ml collagen type I) using the same protocol as described above for the transwell migration assay.

Immunofluorescent staining and confocal microscopy
--------------------------------------------------

T98G cells were grown in labtek chamber slides (BD Biosciences, Heidelberg, Germany), fixed with 4% paraformaldehyde after treatment with BV6, permeabilized with 0.1% Triton-100X for 10 min and stained overnight at 4 °C for F-actin with Oregon green 488 phalloidin (Invitrogen). All images were obtained using a Nikon C1si confocal microscope (Nikon, Tokyo, Japan). Images were computer processed in ImageJ and Adobe Photoshop CS3 (Adobe Systems Inc., San Jose, CA, USA).

Western blotting
----------------

Western blot analysis was performed as described previously^[@bib46]^ using the following antibodies: anti-cIAP1 (R&D Systems, Inc., Wiesbaden-Nordenstadt, Germany), anti-cIAP2 (Epitomics, Burlingam, CA, USA), anti-XIAP and anti-Smac from BD Biosciences, anti-caspase-3, anti-NIK and anti-phospho-p65 from Cell Signaling (Beverly, MA, USA), anti-*β*-actin (Sigma), anti-*α*-tubulin (Calbiochem, Darmstadt, Germany), anti-p50, anti-p65, anti-RelB and anti-TNFR1 from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-p52 (Millipore, Schwalbach, Germany), anti-lamin A/C (Novacastra, Berlin, Germany) and anti-GAPDH (BioTrend, Cologne, Germany). Donkey anti-mouse IgG, donkey anti-rabbit IgG or donkey anti-goat IgG labeled with IRDye infrared dyes were used for fluorescence detection at 700 nm 800 nm (LI-COR Biotechnology, Bad Homburg, Germany). Caspase-3 was immunodetected by enhanced chemoluminescence (Amersham Biosciences, Freiburg, Germany) using an anti-rabbit IgG-HRP as secondary antibody.

Nuclear extractions and EMSA
----------------------------

Nuclear extracts were prepared as previously described.^[@bib47]^ Shortly, cells were washed, scraped, and collected by centrifugation at 2500 r.p.m for 5 min at 4 °C. Cells were resuspended in low salt buffer, lysed for 15 min on ice, followed by addition of a 10% Igepal CA-630 solution and centrifugation. The pelleted nuclei were resuspended in high salt buffer and nuclear supernatants were obtained by centrifugation. DNA-binding activity of NF-*κ*B was analyzed by EMSA and the following sequence was used as specific oligomer for NF-*κ*B: 5′-AGTTGAGGGGACTTTCCCAGGC-3′ (sense). Single-stranded oligonucleotides were labeled with γ-\[32P\]-ATP by T4-polynucleotide kinase (MBI Fermentas 17 GmbH, St. Leon-Rot, Germany), annealed to the complementary oligomer strand and purified on sephadex columns (Illustra Nick Columns, GE Healthcare, Piscataway, NJ, USA). Binding reactions containing 5 *μ*g nuclear extract, 1 *μ*g Poly(dI:dC) (Sigma), labeled oligonucleotide (10 000 c.p.m.) and 5 × binding buffer were incubated for 30 min on ice. Binding complexes were resolved by electrophoresis in non-denaturing 6% polyacrylamide gels using 0.5 × TBE as running buffer and assessed by autoradiography. For EMSA supershift experiments, binding reactions containing 2.5 *μ*g nuclear extract were incubated for 30 min at room temperature with 4 *μ*g of the following antibodies before addition of labeled oligonucleotides: anti-p50 (sc-1190x), anti-p65 (sc-372X), anti-RelB (sc-226X), anti-c-Rel (sc-70X) (all from Santa Cruz) or anti-p52 (Millipore).

Luciferase assay
----------------

The Dual-Luciferase Reporter Assay System (Promega, Mannheim, Germany) was used to determine firefly and *Renilla* luciferase activities according to the manufacturer\'s instructions. Cells were seeded in 12-well plates and transfected both with 3 × *κ*B-firefly luciferase vector containing 3 × *κ*B consensus motif (5′-CCCTGAAAGG-3′) and *Renilla* luciferase vector under the control of the ubiquitin promoter using Fugene 6 Transfection Reagent (Roche Diagnostics). The day after transfection, cells were stimulated with 2.5 *μ*M BV6 or DMSO. After 24 h of stimulation, cells were lysed and luciferase activities were measured with a microplate reader (TECAN Infinite M200). Firefly luciferase values were normalized to *Renilla* luciferase values.

Quantitative RT-PCR
-------------------

Total RNA was extracted using peqGOLD Total RNA kit from Peqlab Biotechnologie GmbH (Erlangen, Germany) according to the manufacturer\'s instructions. In all, 2 *μ*g of total RNA were used to synthetize the corresponding cDNA using RevertAid H Minus First Strand cDNA Synthesis Kit (MBI Fermentas GmbH). To quantify gene expression levels, SYBR-Green based qRT-PCR was performed using the 7900HT fast real-time PCR system from Applied Biosystems (Darmstadt, Germany). Data were normalized on 18S-rRNA expression as reference gene. Primers are listed in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. Melting curves were plotted to verify the specificity of the amplified products. All determinations were performed in triplicate. The relative expression of the target gene transcript and reference gene transcript was calculated as ΔΔC~t~. Two independent experiments were done for each gene.

CAM assay and primary GBM cultures
----------------------------------

CAM assay was done as described previously.^[@bib28]^ Briefly, 1 × 10^6^ T98G cells were resuspended in 10 *μ*l serum-free medium and 10 *μ*l Matrigel matrix (BD Biosciences) after treatment with or without 2.5 *μ*M BV6 for 24 h and implanted on the CAM of fertilized chicken eggs on day 8 of incubation. Four days after inoculation, tumors were excised with the surrounding CAM, fixed in 4% paraformaldehyde, embedded in paraffin, cut in 5 *μ*m sections and stained with 1 : 1 hematoxylin and 0.5% eosin solution for histological analysis. Images were digitally recorded with an SZ61 microscope (Olympus, Center Valley, PA, USA) and tumor area was analyzed using ImageJ digital imaging software (NIH). Primary GBM cultures (GBM1, GBM2) were established from surgical specimens obtained from two patients with grade 4 glioma and were characterized and cultured as described previously.^[@bib48]^ The study was approved by the ethics committee, Medical Faculty, University of Frankfurt.

Statistical Analysis
--------------------

Statistical significance was assessed by two-sided Student\'s *t*-test using Microsoft Excel (Microsoft Deutschland GmbH, Unterschleißheim, Germany).
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CAM

:   chicken chorioallantoic membrane

cIAP

:   cellular inhibitor of apoptosis

CXCR4

:   CXC chemokine receptor 4

DMSO

:   dimethylsulfoxyde

EMSA

:   electrophoretic mobility shift assay

F-actin

:   filamentous actin

FITC

:   fluorescein

GBM

:   glioblastoma

IAP

:   inhibitor of apoptosis

IL-8

:   interleukin 8

I*κ*Bα-SR

:   I*κ*B*α* superrepressor

MCP-1

:   monocyte chemoattractant protein 1

MMPs

:   matrix metalloproteinases

MTT

:   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

NF-*κ*B

:   nuclear factor *κ*B

NIK

:   NF-*κ*B-inducing kinase

uPA

:   urokinase-type plasminogen activator

Smac

:   second mitochondrial activator of caspases

TNF*α*

:   tumor necrosis factor *α*

TNFR1

:   tumor necrosis factor receptor 1

XIAP

:   X-linked inhibitor of apoptosis
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![BV6 triggers cell elongation of GBM cells. (**a**) T98G, U87MG and LN229 GBM cells were treated for 24 h with indicated concentrations of BV6 or DMSO. Cell viability was measured by MTT assay and is expressed as the percentage of untreated controls. (**b**) T98G, U87MG and LN229 cells were treated for 24 h with 2.5 *μ*M BV6 or DMSO. Expression levels of cIAP1, cIAP2, XIAP and caspase-3 were analyzed by western blotting. Expression of *β*-actin served as loading control. (**c** and **d**) T98G cells were treated for 24 h with 2.5 *μ*M BV6 or DMSO. Cell morphology was analyzed by phase-contrast microscope; scale bar: 250 *μ*m (**c**). Cell elongation was quantified by measuring cell length and width and by calculating cell elongation index (length/width); fold increase in elongation index in the presence and absence of BV6 is shown (**d**). (**e**) T98G cells were treated for 24 h with 2.5 *μ*M BV6 or DMSO. Polymerization of F-actin was analyzed by phalloidin staining; scale bar: 20 *μ*m. In (**b**, **c** and **e**), representative experiments of three independent experiments are shown. In (**a** and **d**), mean+S.D. of three independent experiments performed in triplicate are shown; \*\*\**P*\<0.005](cddis201370f1){#fig1}

![BV6 triggers migration and invasion of GBM cells. (**a** and **b**) T98G, U87MG and LN229 cells were treated with 2.5 *μ*M BV6 or DMSO and allowed to migrate for 24 h in a transwell migration chamber. Migrated cells were fixed, stained with crystal violet and pictures were taken by phase-contrast microscope (scale bar: 500 *μ*m); a representative experiment of three independent experiments is shown (**a**). Migration was quantified by dissolution of crystal violet staining and determination of optical density; fold increase in migration is shown (**b**). (**c**) T98G, U87MG and LN229 cells were cultivated for 24 h in FITC-collagen containing 2.5 *μ*M BV6 or DMSO. Invasion was assessed by determining the amount of FITC released into the supernatant. Fold increase in invasion in the presence and absence of BV6 is shown. (**d**) T98G cells were treated for 24 h with 2.5 *μ*M BV6 or DMSO for *in vivo* invasion assay. After treatment, one million cells were seeded on the CAM of chicken embryos and allowed to grow for 4 days. Tumor formation (tumor\>0.5 cm^3^) and infiltrative growth (growth of tumor cells inside the CAM) were analyzed by hematoxylin eosin-stained paraffin sections of the CAM. Representative pictures from three independent experiments are shown (*n*=30 eggs). Lower magnification (upper pictures): × 3; higher magnification (lower pictures): × 4; scale bar: 500 *μ*m. The number and percentage of tumor formation and infiltrative tumors are indicated. In (**b** and **c**), mean+S.D. of three independent experiments performed in duplicate are shown; \**P*\<0.05](cddis201370f2){#fig2}

![BV6 activates the non-canonical NF-*κ*B pathway. (**a**) T98G cells were treated for indicated times with 2.5 *μ*M BV6 or DMSO; stimulation with 10 ng/ml TNF*α* for 5 min was used as positive control. Phosphorylation and expression of I*κ*B*α* were analyzed by western blotting. Expression of *α*-tubulin served as loading control. (**b**) T98G cells were treated for indicated times with 2.5 *μ*M BV6 or DMSO. Expression levels of NIK, p100, p52 and cIAP1 were analyzed by western blotting. Expression level of GAPDH served as loading control. (**c**) T98G, U87MG and LN229 cells were treated for 24 h with 2.5 *μ*M BV6 or DMSO. Expression levels of NIK, p100 and p52 were analyzed by western blotting. Expression of GAPDH served as loading control. (**d**) T98G, U87MG and LN229 cells were treated for 24 h with 2.5 *μ*m BV6 or DMSO; stimulation with 10 ng/ml TNF*α* for 1 h was used as positive control. Expression levels of p100, p52, p50, phospho-p65 (p-p65) and p65 were analyzed in cytoplasmic (C) and nuclear (N) fractions by western blotting. *α*-tubulin served as loading control for cytoplasmic fractions and lamin A/C for nuclear fractions. (**e**) T98G cells were treated for indicated times with 2.5 *μ*M BV6 or DMSO; stimulation with 10 ng/ml TNF*α* for 1 h was used as positive control. Nuclear extracts were analyzed for NF-*κ*B DNA-binding activity by EMSA. (**f**) T98G cells were treated for 6 h with 2.5 *μ*M BV6 or DMSO or with 10 ng/ml TNF*α* for 1 h. Nuclear extracts were analyzed for the composition of NF-*κ*B DNA-binding complexes by EMSA supershift using the indicated antibodies. (**g**) T98G cells were treated for 24 h with 2.5 *μ*M BV6 or DMSO. NF-*κ*B transcriptional activity was determined by luciferase assay and fold increase in luciferase activity is shown. Mean+S.D. of three independent experiments performed in triplicate are shown; \*\*\**P*\<0.005. In (**a**--**f**), representative experiments of three (**a**--**e**) or two (**f**) independent experiments are shown](cddis201370f3){#fig3}

![NF-*κ*B is required for BV6-induced cell elongation, migration and invasion. (**a**) T98G cells were transduced with I*κ*B*α*-SR or vector control and analyzed for expression of I*κ*B*α* by western blotting. *α*-tubulin expression served as a loading control. (**b**) T98G cells stably expressing I*κ*B*α*-SR or vector control were treated for 3 h with 2.5 *μ*M BV6 or DMSO, stimulation with 10 ng/ml TNF*α* for 1 h was used as positive control. Nuclear extracts were analyzed by EMSA for NF-*κ*B DNA-binding activity. (**c**) T98G cells stably expressing I*κ*B*α*-SR or vector control were treated for 24 h with 2.5 *μ*M BV6 or DMSO. Expression levels of NIK, p100, p52, RelB, cIAP1 and cIAP2 were analyzed by western blotting. Expression of GAPDH served as loading control. (**d** and **e**) T98G cells stably expressing I*κ*B*α*-SR or vector control were treated for 24 h with 2.5 *μ*M BV6 or DMSO. Cell morphology was analyzed by phase-contrast microscope; scale bar: 50 *μ*m. A representative experiment of three experiments is shown (**d**). Cell elongation was quantified by measuring cell length and width and by calculating cell elongation index (length/width); fold increase in elongation index is shown (**e**). (**f**) T98G cells transduced with I*κ*B*α*-SR or vector control were treated with 2.5 *μ*M BV6 or DMSO and allowed to migrate for 24 h in a transwell migration chamber. Migrated cells were fixed and stained with crystal violet. Migration was quantified by dissolution of crystal violet staining and determination of optical density. (**g**) T98G cells transduced with I*κ*B*α*-SR or vector control were treated with 2.5 *μ*M BV6 or DMSO and allowed to invade for 24 h in a collagen-coated transwell migration chamber. Invasive cells were fixed and stained with crystal violet. Invasion was quantified by dissolution of the crystal violet staining and determination of optical density. In (**a**--**d**), a representative experiment of two (**a**--**c**) or three (**d**) independent experiments is shown. In (**e**--**g**), mean+S.D. of three independent experiments are shown; \**P*\<0.05; \*\**P*\<0.01; n.s. not significant](cddis201370f4){#fig4}

![TNF*α* is required for BV6-induced cell elongation, migration and invasion. (**a**) T98G cells were treated for indicated times with 2.5 *μ*M BV6 or DMSO. TNF*α* mRNA levels were analyzed by quantitative RT-PCR and fold increase in TNF*α* mRNA levels is shown. Mean+S.D. values of two independent experiments are shown. (**b**) T98G cells were treated with 2.5 *μ*M BV6 or DMSO. mRNA levels of indicated NF-*κ*B target genes were analyzed by quantitative RT-PCR and are shown as fold increase for maximal induction (IL-8 and MCP-1 after 6 h, CXCR4 after 9 h, uPA and MMP9 after 24 h). Mean+S.D. values of two independent experiments are shown. (**c**--**e**) T98G cells were treated for 24 h with 2.5 *μ*M BV6 and/or 100 *μ*g/ml Enbrel. Cell morphology was analyzed by phase-contrast microscope. Cell elongation was quantified by measuring cell length and width and by calculating cell elongation index (length/width); fold increase in elongation index is shown (**c**). Migrated cells were fixed and stained with crystal violet. Migration was quantified by dissolution of crystal violet staining and determination of optical density (**d**). Cells were allowed to invade in a collagen-coated transwell migration chamber; invasive cells were fixed, stained with crystal violet and optical density was measured (**e**). In (**c**--**e**) mean+S.D. values of three independent experiments performed in triplicate (**c**) and duplicate (**d** and **e**) are shown; \**P*\< 0.05; \*\**P*\<0.01; n.s. not significant](cddis201370f5){#fig5}

![TNFR1 knockdown inhibits BV6-induced cell elongation, migration and invasion. (**a**) T98G cells were lentivirally transduced with shRNA against TNFR1 or vector control and knockdown of TNFR1 was assessed by western blotting. GAPDH expression served as loading control. (**b**--**d**) T98G cells transduced with shRNA against TNFR1 or control vector were treated for 24 h with 2.5 *μ*M BV6. Cell morphology was analyzed by phase-contrast microscope. Cell elongation was quantified by measuring cell length and width and by calculating cell elongation index (length/width); fold increase in elongation index is shown (**b**). Migrated cells were fixed and stained with crystal violet. Migration was quantified by dissolution of crystal violet staining and determination of optical density (**c**). Cells were allowed to invade in a collagen-coated transwell migration chamber; invasive cells were fixed, stained with crystal violet and optical density was measured (**d**). In (**a**), a representative experiment of two independent experiments is shown, in (**b**--**d**) mean+S.D. values of three independent experiments performed in triplicate (**b**) or duplicate (**c** and **d**) are shown; \**P*\<0.05; n.s. not significant](cddis201370f6){#fig6}

![NIK is required for BV6-induced cell elongation, migration and invasion. (**a**) T98G cells transduced with shRNA against NIK or vector control were treated for 24 h with 2.5 *μ*M BV6. Expression levels of NIK, p100, p52 and cIAP1 were analyzed by western blotting. Expression of GAPDH served as loading control. (**b**) T98G cells transduced with shRNA against NIK (shNIK) or vector control were treated for 2 and 24 h with 2.5 *μ*M BV6, stimulation with 10 ng/ml TNF*α* for 1 h was used as positive control. Nuclear extracts were prepared and analyzed for NF-*κ*B DNA-binding activity by EMSA. NIK knockdown slightly reduced BV6-stimulated NF-*κ*B DNA-binding after treatment with BV6 for 24 h compared with non-silencing control cells. (**c**--**e**) T98G cells transduced with shRNA against NIK or vector control were treated for 24 h with 2.5 *μ*M BV6. Cell morphology was analyzed by phase-contrast microscope. Cell elongation was quantified by measuring cell length and width and by calculating cell elongation index (length/width); fold increase in elongation index is shown (**c**). Migrated cells were fixed and stained with crystal violet. Migration was quantified by dissolution of crystal violet staining and determination of optical density (**d**). Cells were allowed to invade in a collagen-coated transwell migration chamber; invasive cells were fixed, stained with crystal violet and optical density was measured (**e**). (**f**) T98G cells transduced with shRNA against NIK or vector control were treated for indicated times with 2.5 *μ*M BV6. TNF*α* mRNA levels were analyzed by quantitative RT-PCR and fold increase in TNF*α* mRNA levels is shown. (**g**) T98G cells transduced with shRNA against NIK or vector were treated with 2.5 *μ*M BV6. mRNA levels of indicated NF-*κ*B target genes were analyzed by quantitative RT-PCR and are shown as fold increase for maximal induction (IL-8 and MCP-1 after 6 h, and MMP9 after 24 h). In (**a** and **b**), representative experiments from two (**a**) or three (**b**) experiments are shown. In (**c**--**g**), mean+S.D. values of three (**c**--**e**) or two (**f** and **g**) independent experiments performed in triplicate (**c**, **f** and **g**) and duplicate (**d** and **e**) are shown; \**P*\<0.05; \*\**P*\<0.01; n.s. not significant](cddis201370f7){#fig7}

![BV6 triggers cell elongation, migration and invasion of primary GBM cells. (**a**) Primary GBM cells derived from two distinct specimens (GBM1, GBM2) were treated for 24 h with indicated concentrations of BV6. Cell viability was measured by MTT assay and is expressed as the percentage of untreated controls. (**b**) Primary GBM cells were treated with BV6 (GBM1: 1 *μ*M BV6, GBM2: 0.8 *μ*M BV6) for 24 h. Expression levels of cIAP1, cIAP2, XIAP and caspase-3 were analyzed by western blotting. Expression level of GAPDH served as loading control. (**c**) Primary GBM cells were treated with BV6 (GBM1: 1 *μ*M BV6, GBM2: 0.8 *μ*M BV6) for 24 h. Expression levels of p100, p52 and cIAP1 were analyzed by western blotting. Expression level of GAPDH served as a loading control. (**d**--**f**) Primary GBM cells were treated with BV6 (GBM1: 1 *μ*M BV6, GBM2: 0.8 *μ*M BV6) for 24 h. Cell morphology was analyzed by phase-contrast microscope. Cell elongation was quantified by measuring cell length and width and by calculating cell elongation index (length/width); fold increase in elongation index is shown (**d**). Migrated cells were fixed and stained with crystal violet. Migration was quantified by dissolution of crystal violet staining and determination of optical density (**e**). Cells were allowed to invade in a collagen-coated transwell migration chamber; invasive cells were fixed, stained with crystal violet and optical density was measured (**f**). In (**a**, **d**--**f**), mean+S.D. values of three independent experiments performed in triplicate (**a** and **d**) and in duplicate (**e** and **f**) are shown; \**P*\<0.05. In (**b** and **c**), representative experiments from two experiments are shown](cddis201370f8){#fig8}
